Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle Fanale, Loretta Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. Hagemeister, Nathan Fowler

Research output: Contribution to journalArticlepeer-review

Abstract

R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with advanced follicular lymphoma (FL) may improve remission rates. We now report 10-year follow-up results from our sequential treatment approach with an abbreviated regimen of R-FND followed by 90YIT consolidation and rituximab maintenance. Forty-nine patients were enrolled; 47 received treatment. Patients had high-risk (FLIPI score ≥3) FL of grade 1–3A and stage III/IV with adequate hematologic function. Following R-FND, the complete and partial response rates were 91% and 8.5%, respectively. After 90YIT consolidation, the CR rate increased to 97%. The 10-year PFS rate was 49%. The most common non-hematologic, grade 3 or 4 adverse events were fatigue, dyspnea, and myalgia. Five developed myelodysplastic syndrome (MDS). This treatment approach is most appropriate in FLIPI-based high-risk patients whose outlook with standard therapy is inadequate.

Original languageEnglish (US)
Pages (from-to)58-67
Number of pages10
JournalLeukemia and Lymphoma
Volume62
Issue number1
DOIs
StatePublished - 2021

Keywords

  • B-cell lymphoma
  • BCL2
  • Fludarabine
  • ibritumomab tiuxetan
  • radioimmunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

MD Anderson CCSG core facilities

  • Biostatics Resource Group

Fingerprint

Dive into the research topics of 'Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma'. Together they form a unique fingerprint.

Cite this